Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.74 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.64 |
| ▸ | PIM1 | P11309 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.64 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.56 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.52 |
| ▸ | TEK | Q02763 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29967106 | 1.00 | PARP1 (0.74) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 | |
| SCHEMBL6922381 | 0.88 | PARP1 (0.63) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 | |
| SCHEMBL29709603 | 0.85 | PARP1 (1.00) | PARP1CHEK1PIM1ALDH1A1IP6K1 | |
| SCHEMBL2191067 | 0.85 | PARP1 (1.00) | PARP1CHEK1PIM1ALDH1A1IP6K1 | |
| Hydrochloric Acid SCHEMBL30141968 | 0.84 | PARP1 (0.96) | PARP1CHEK1PIM1IP6K1IP6K3 | |
| SCHEMBL6921163 | 0.82 | TEK (0.59) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 | |
| SCHEMBL2051742 | 0.82 | IP6K1 (0.59) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 | |
| SCHEMBL2047492 | 0.79 | IP6K1 (0.59) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 | |
| SCHEMBL5875318 | 0.78 | IP6K1 (0.61) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 | |
| SCHEMBL643424 | 0.78 | ALDH1A1 (1.00) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107814773-B | Quinazolinone-containing diaryl urea compound and preparation method and application thereof | 西安交通大学 | 2020-05-22 | — | — | CN | claimed |
| CN-103304492-A | Synthesis method of EGFR (epidermal growth factor receptor) inhibitor Dacomitinib | HUNAN OUYA BIOLOG CO LTD | 2013-09-18 | — | — | CN | claimed |
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250145607-A1 | Modulators of CAMKK2 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-05-08 | — | — | US | disclosed |
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-118575818-A | Application of compound shown in formula (I) in preventing and treating agricultural plant pathogenic fungal diseases | 广西田园生化股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| EP-4412999-A1 | MODULATORS OF CAMKK2 AS LIGAND DIRECTED DEGRADERS | Celgene Corporation (US) | 2024-08-14 | — | — | EP | disclosed |
| US-12012400-B2 | Method of the preparation of fused multicyclic compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2024-06-18 | — | — | US | disclosed |
| EP-4373816-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-118076603-A | CAMKK2 modulators as ligand-directed degradants | 细胞基因公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117466942-A | Chiral secondary phosphine oxide compound, chiral quinazolinone/pyrimidinone ring derivative based on chiral secondary phosphine oxide compound and application of chiral quinazolinone/pyrimidinone ring derivative | 中山大学 | 2024-01-30 | — | — | CN | disclosed |
| WO-1997030035-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997030044-A1 | QUINAZOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997022596-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
| US-5580870-A | ANTICARCINOGENIC AGENTS | ZENECA LIMITED (GB) | 1996-12-03 | — | — | US | disclosed |
| EP-0602851-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1996-10-09 | — | — | EP | disclosed |
| US-5475001-A | Quinazoline derivatives | ZENECA LIMITED (GB) | 1995-12-12 | — | — | US | disclosed |
| WO-1995003283-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS | ZENECA LIMITED (GB) | 1995-02-02 | — | — | WO | disclosed |
| EP-0635498-A1 | Quinazoline derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | disclosed |
| EP-0602851-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1994-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012400-B2 | Method of the preparation of fused multicyclic compounds | CYP1B1, CYP2W1, CYP2F1 | PARP1 312/4885CHEK1 3459/4885PIM1 2502/4885 |
| US-20250145607-A1 | Modulators of CAMKK2 as Ligand Directed Degraders | CAMKK2, CAMKK1, CAMK1D | PARP1 591/4885CHEK1 1343/4885PIM1 1601/4885 |
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | USP7, USP47, USP2 | PARP1 1909/4885CHEK1 1582/4885PIM1 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.